Maxim Group analyst Michael Okunewitch maintained a Buy rating on Longeveron (LGVN – Research Report) yesterday and set a price target of $14.00. The company’s shares opened today at $6.15.
According to TipRanks, Okunewitch is an analyst with an average return of -19.6% and a 29.41% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Kiora Pharmaceuticals, Citius Pharmaceuticals, and Longeveron.
Currently, the analyst consensus on Longeveron is a Moderate Buy with an average price target of $14.00.
See the top stocks recommended by analysts >>
LGVN market cap is currently $126.1M and has a P/E ratio of -6.97.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LGVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
Read More on LGVN:
- Small Cap Consumer Research Sticks to Their Buy Rating for urban-gro (UGRO)
- Barclays Sticks to Their Hold Rating for Plains GP Holdings (PAGP)
- Goldman Sachs Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)
- Simply Good Foods (SMPL) Gets a Buy from Goldman Sachs
- Goldman Sachs Keeps Their Buy Rating on UDR (UDR)
